Aurdan Capital Management LLC Invests $312,000 in Stryker Co. (NYSE:SYK)

Aurdan Capital Management LLC bought a new stake in shares of Stryker Co. (NYSE:SYK - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 867 shares of the medical technology company's stock, valued at approximately $312,000.

Other hedge funds also recently modified their holdings of the company. Elefante Mark B purchased a new position in shares of Stryker during the fourth quarter valued at approximately $337,000. Chicago Capital LLC raised its stake in shares of Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock valued at $70,228,000 after buying an additional 5,841 shares during the period. Appleton Partners Inc. MA raised its stake in shares of Stryker by 5.0% in the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after buying an additional 1,400 shares during the period. Metis Global Partners LLC raised its stake in shares of Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock valued at $6,064,000 after buying an additional 1,561 shares during the period. Finally, Fred Alger Management LLC raised its stake in shares of Stryker by 415.8% in the fourth quarter. Fred Alger Management LLC now owns 24,011 shares of the medical technology company's stock valued at $8,664,000 after buying an additional 19,356 shares during the period. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.20% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of SYK stock traded down $1.09 on Friday, reaching $381.26. The stock had a trading volume of 388,535 shares, compared to its average volume of 1,336,556. The stock has a market cap of $145.52 billion, a P/E ratio of 49.14, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company has a 50 day simple moving average of $368.57 and a 200 day simple moving average of $376.25.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the business posted $2.50 EPS. Equities research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker's dividend payout ratio is currently 45.41%.

Analysts Set New Price Targets

SYK has been the topic of a number of analyst reports. Barclays boosted their price objective on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. BTIG Research set a $403.00 target price on Stryker and gave the company a "buy" rating in a report on Monday, April 14th. Roth Mkm upped their price target on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Sanford C. Bernstein set a $450.00 price target on Stryker in a research report on Monday, May 5th. Finally, Wall Street Zen lowered Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $427.30.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.